ArticleClinicoEconomics and outcomes research : CEOR2026

Short-Term Cost per Responder of Lebrikizumab versus Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia: A Model-Based Payer Analysis.

No numbers read from the abstract.

Not cited yet